Enliven Therapeutics, Inc. (ELVN)
NASDAQ: ELVN · Real-Time Price · USD
20.89
+0.62 (3.06%)
Sep 2, 2025, 4:00 PM - Market closed
Enliven Therapeutics Stock Forecast
Stock Price Forecast
The 5 analysts that cover Enliven Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $41.2, which forecasts a 97.22% increase in the stock price over the next year. The lowest target is $27 and the highest is $52.
Price Target: $41.2 (+97.22%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Jul 2, 2025.
Analyst Ratings
The average analyst rating for Enliven Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 3 | 4 | 4 | 4 | 4 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 4 | 5 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $40 → $48 | Strong Buy | Maintains | $40 → $48 | +129.78% | Jul 2, 2025 |
| Goldman Sachs | Goldman Sachs | Strong Buy Initiates $37 | Strong Buy | Initiates | $37 | +77.12% | Jun 16, 2025 |
| Baird | Baird | Buy Maintains $40 → $52 | Buy | Maintains | $40 → $52 | +148.92% | Jun 16, 2025 |
| Jones Trading | Jones Trading | Strong Buy Maintains $36 → $27 | Strong Buy | Maintains | $36 → $27 | +29.25% | May 16, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $39 → $40 | Strong Buy | Maintains | $39 → $40 | +91.48% | May 15, 2025 |
Financial Forecast
Revenue This Year
10.20K
Revenue Next Year
12.75K
from 10.20K
Increased by 25.00%
EPS This Year
-1.98
from -1.89
EPS Next Year
-2.33
from -1.98
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 52,500 | 52,500 | |||
| Avg | 10,200 | 12,750 | |||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | 414.7% | |||
| Avg | - | 25.0% | |||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.96 | -2.05 | |||
| Avg | -1.98 | -2.33 | |||
| Low | -1.96 | -2.76 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.